{"drugs":["Ceftolozane\/Tazobactam","Zerbaxa"],"mono":{"0":{"id":"931323-s-0","title":"Generic Names","mono":"Ceftolozane\/Tazobactam"},"1":{"id":"931323-s-1","title":"Dosing and Indications","sub":[{"id":"931323-s-1-4","title":"Adult Dosing","mono":"<ul><li>The US Food and Drug Administration has received reports of medication errors due to confusion about the strengths of component drugs listed on the vial. Each vial contains 1.5 g total (equivalent to ceftolozane 1 g and tazobactam 0.5 g).<\/li><li><b>Complicated urinary tract infection:<\/b> 1.5 g (ceftolozane 1 g\/tazobactam 0.5 g) IV infused over 1 hour every 8 hours for 7 days; duration is dependant on severity and site of infection and clinical and bacteriological progress<\/li><li><b>Infectious disease of abdomen, Complicated disease, in combination with metronidazole:<\/b> 1.5 g (ceftolozane 1 g\/tazobactam 0.5 g) IV infused over 1 hour every 8 hours for 4 to 14 days, depending on severity and site of infection and clinical and bacteriological progress; give with metronidazole 500 mg IV every 8 hours<\/li><li><b>Pyelonephritis:<\/b> 1.5 g (ceftolozane 1 g\/tazobactam 0.5 g) IV infused over 1 hour every 8 hours for 7 days; duration is dependant on severity and site of infection and clinical and bacteriological progress<\/li><\/ul>"},{"id":"931323-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy have not been established in pediatric patients."},{"id":"931323-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment, mild:<\/b> No adjustment recommended<\/li><li><b>Renal impairment (estimated CrCl 30 to 50 mL\/min):<\/b> Reduce to ceftolozane 500 mg\/tazobactam 250 mg IV infused over 1 hour every 8 hours.<\/li><li><b>Renal impairment (estimated CrCl 15 to 29 mL\/min):<\/b> Reduce to ceftolozane 250 mg\/tazobactam 125 mg IV infused over 1 hour every 8 hours.<\/li><li><b>ESRD on hemodialysis:<\/b> Single loading dose of ceftolozane 500 mg\/tazobactam 250 mg IV infused over 1 hour followed by ceftolozane 100 mg\/tazobactam 50 mg IV infused over 1 hour every 8 hours for the remainder of the treatment period; dialysis days, give the dose at the earliest time following dialysis completion<\/li><li><b>Hepatic impairment:<\/b> No adjustment recommended<\/li><li><b>Geriatric:<\/b> No adjustments recommended; select dose carefully and base on renal function<\/li><li><b>Race:<\/b> No adjustment recommended<\/li><\/ul>"},{"id":"931323-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Complicated urinary tract infection<\/li><li>Infectious disease of abdomen, Complicated disease, in combination with metronidazole<\/li><li>Pyelonephritis<\/li><\/ul>"}]},"3":{"id":"931323-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931323-s-3-9","title":"Contraindications","mono":"hypersensitivity to ceftolozane, tazobactam, piperacillin\/tazobactam, or any other beta-lactams.<br\/>"},{"id":"931323-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea has been reported, including cases occurring more than 2 months after administration; discontinue use and institute appropriate medical management if suspected or confirmed<\/li><li>Immunologic:<\/li><li>-- Serious and possibly fatal hypersensitivity reactions have been reported<\/li><li>-- Cross sensitivity may occur<\/li><li>-- Increased risk of developing drug-resistant bacteria if administered in absence of proven or strongly suspected bacterial infection<\/li><li>Renal:<\/li><li>-- Decreased efficacy has been reported in patients with baseline creatinine clearance of 30 to less than or equal to 50 mL\/min; monitoring recommended<\/li><li>-- Increased risk of adverse effects in patients with moderate or severe renal impairment and those with ESRD on hemodialysis; monitoring recommended and dose adjustments required<\/li><li>Other:<\/li><li>-- Increased risk of adverse effects in elderly patients; monitoring recommended and dose adjustments may be warranted<\/li><\/ul>"},{"id":"931323-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"931323-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931323-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (6.2%), Nausea (2.8% to 7.9%)<\/li><li><b>Neurologic:<\/b>Headache (2.5% to 5.8%)<\/li><li><b>Other:<\/b>Fever (1.7% to 5.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Renal:<\/b>Renal impairment (Less than 1%)<\/li><\/ul>"},"6":{"id":"931323-s-6","title":"Drug Name Info","sub":{"0":{"id":"931323-s-6-17","title":"US Trade Names","mono":"Zerbaxa<br\/>"},"2":{"id":"931323-s-6-19","title":"Class","mono":"<ul><li>Antibiotic Combination<\/li><li>Beta-Lactamase Inhibitor<\/li><li>Cephalosporin<\/li><\/ul>"},"3":{"id":"931323-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931323-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931323-s-7","title":"Mechanism Of Action","mono":"Ceftolozane is a cephalosporin class bactericidal agent that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Tazobactam has low affinity for PBPs, but does irreversibly inhibit certain penicillinases and cephalosporinases and covalently binds to some chromosomal and plasmid-mediated bacterial beta-lactamases.<br\/>"},"8":{"id":"931323-s-8","title":"Pharmacokinetics","sub":[{"id":"931323-s-8-23","title":"Absorption","mono":"<ul><li>Ceftolozane, Tmax, IV: 1.07 hours<\/li><li>Tazobactam, Tmax, IV: 1.01 hours<\/li><\/ul>"},{"id":"931323-s-8-24","title":"Distribution","mono":"<ul><li>Ceftolozane, Protein binding: 16% to 21%<\/li><li>Ceftolozane, Vd: 13.5 L<\/li><li>Tazobactam, Protein binding: 30%<\/li><li>Tazobactam, Vd: 18.2 L<\/li><\/ul>"},{"id":"931323-s-8-25","title":"Metabolism","mono":"<ul><li>Ceftolozane: Negligible<\/li><li>Tazobactam: Hydrolysis<\/li><li>Tazobactam: Substrate of OAT1 transporter and OAT3 transporter<\/li><\/ul>"},{"id":"931323-s-8-26","title":"Excretion","mono":"<ul><li>Ceftolozane, Renal: Greater than 95% unchanged<\/li><li>Ceftolozane, Renal clearance: 3.41 to 6.69 L\/hr<\/li><li>Ceftolozane, Total body clearance: 4.1 to 6.73 L\/hr (ceftolozane)<\/li><li>Tazobactam, Renal: Greater than 80% unchanged<\/li><li>Dialyzable: Yes, approximately two-thirds removed<\/li><\/ul>"},{"id":"931323-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Ceftolozane: 3.12 hours<\/li><li>Tazobactam: 1.03 hours<\/li><\/ul>"}]},"9":{"id":"931323-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Reconstitute vial with 10 mL of sterile water or NS for injection and gently shake to yield a final concentration of 1.5 g (ceftolozane 1 g\/tazobactam 0.5 g) per 11.4 mL.<\/li><li>Further dilute the reconstituted solution within 1 hour.<\/li><li>Do not administer reconstituted drug without further dilution.<\/li><li>Dilute by adding desired volume to 100 mL of NS or D5W. Add 11.4 mL for concentration of 1.5 g (ceftolozane 1 g\/tazobactam 0.5 g dose), 5.7 mL for 750 mg (ceftolozane 500 mg\/tazobactam 250 mg dose), 2.9 mL for 375 mg (ceftolozane 250 mg\/tazobactam 125 mg dose), or 1.2 mL for 150 mg (ceftolozane 100 mg\/tazobactam 50 mg dose).<\/li><li>Do not mix with other drugs or solutions containing other drugs.<\/li><li>Administer the diluted solution within 24 hours if stored at room temperature, or within 7 days when refrigerated (2 to 8 degrees C or 36 to 46 degrees F).<\/li><li>Do not freeze either the reconstituted or diluted solution.<\/li><li>Administer all doses via IV infusion over 1 hour.<\/li><\/ul>"},"10":{"id":"931323-s-10","title":"Monitoring","mono":"<ul><li>Improvement in signs and symptoms of infection are indicative of efficacy<\/li><li>Patients with changing renal function; CrCl at least daily<\/li><li>Elderly patients; consider monitoring renal function.<\/li><\/ul>"},"11":{"id":"931323-s-11","title":"How Supplied","mono":"<b>Zerbaxa<\/b><br\/>Intravenous Powder for Solution: (Ceftolozane - Tazobactam) 1 GM-0.5 GM<br\/>"},"13":{"id":"931323-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects include nausea, headache, and pyrexia.<\/li><li>Instruct patient to report severe watery or bloody diarrhea, which may occur more than 2 months after last dose.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given on a regular schedule and patient should complete the full course of therapy.<\/li><\/ul>"}}}